CeleCor Therapeutics reported a positive pivotal CeleBrate Phase 3 trial for a rapid‑onset treatment of myocardial infarction, presented in a late‑breaking session at the American Heart Association. The company said the data met primary endpoints and will be used to support an FDA Biologics License Application slated for submission in the coming regulatory cycle. The readout, if sustained through review, could establish a new acute‑care therapeutic option for heart attack management. CeleCor will focus on regulatory engagement, manufacturing scale‑up and payer conversations to secure adoption in emergency settings.